CLK1 Inhibitors

CLK1 inhibitors, as detailed in the table, are primarily chemicals that indirectly affect the activity of CLK1 by modulating related kinases or splicing processes. CLK1 plays a significant role in the regulation of alternative splicing by phosphorylating SR proteins, which are essential components of the spliceosome.The main approach to indirectly inhibiting CLK1 involves targeting its kinase activity. Compounds like TG003 and KH-CB19 are known to inhibit CLK1, thereby impacting the phosphorylation of SR proteins and influencing alternative splicing. Chlorhexidine, though primarily known as an antimicrobial agent, has been found to inhibit CLK1 activity. Cdc2-like kinase inhibitors, while not specific, can also affect CLK1 due to the similarity in their kinase domains. Harmine, a DYRK inhibitor, could potentially influence CLK1 due to cross-reactivity among kinases. Indirubin and its derivatives, including Drubin, are non-selective kinase inhibitors that may inhibit CLK1 among other kinases. Leucettine L41, targeting both CLK1 and DYRK1A, can also influence alternative splicing regulated by CLK1. 5-Iodotubercidin is primarily an adenosine kinase inhibitor but has been shown to have inhibitory effects on CLK1 as well. Harmaline, related to harmine, could potentially affect CLK1 activity. Lastly, Quercetin, a plant flavonoid known for its broad kinase inhibitory activity, might impact CLK1 among other kinases.